
Share
Everyone is tracking which BCI company builds the best hardware. But the real contest may be about which applications can displace existing standards of care, and that race has very different winners.
In February 2025, the FDA approved Medtronic's BrainSense Adaptive deep brain stimulation system, a closed-loop device that reads a patient's neural signals and adjusts therapy in real time. Medtronic called the U.S. rollout the largest commercial launch of brain-computer interface technology ever undertaken.
That's a startling claim. So why does almost nobody mention Medtronic when they talk about the BCI race?
The answer tells us something important about how medical innovation actually spreads, and it matters for patients waiting on breakthroughs that haven't arrived yet.
BrainSense succeeded commercially because it entered healthcare as something the system already recognized: an improvement on deep brain stimulation, a therapy doctors already understood, with patients already identified and reimbursement pathways already built. The market didn't have to be convinced that neural technology belonged in care. It already believed that. BrainSense simply advanced a standard that existed.
Compare that to the companies most people associate with the BCI race: Neuralink, Synchron, Precision Neuroscience, Paradromics, Blackrock Neurotech, INBRAIN Neuroelectronics, and a growing list of newer entrants. The conversation around them tends to focus on architecture. Is the electrode array penetrating the brain tissue or sitting on its surface? Is it placed through blood vessels? How many electrodes, how much bandwidth, how many patients implanted so far?
Those questions matter. But they may not be the questions that determine which applications actually reach patients at scale.
Think about how artificial intelligence spread through industries. Nobody expected one AI application to win and become "the AI market." AI turned out to be an enabling capability, applied separately to hundreds of distinct problems, each with its own users, competitors, and adoption path.
BCI may follow the same pattern. The underlying capability, reading and interpreting neural signals, can restore communication for someone who has lost the ability to speak. It can enable control of digital devices or home environments. It can restore movement. It can map brain activity for surgical planning. It can adjust a therapy automatically, the way BrainSense does.
These are genuinely different markets, even when they share the same core technology. And in healthcare, that distinction decides almost everything. Being able to do something new does not automatically give the system a reason to change what it already trusts and already does.

For people living with ALS, severe paralysis, or other devastating neurological conditions, the unmet need is real and urgent. Nobody disputes that the case for innovation exists. But unmet need alone doesn't determine when or whether a technology scales. A breakthrough still has to become part of what the healthcare system routinely does for a specific kind of patient. Clinicians have to learn which patients qualify. Families have to trust the intervention enough to pursue it. Someone has to refer the patient. Payers need a basis for covering the cost. Eventually these decisions need to repeat often enough that the new approach becomes expected, not exceptional.
That journey, from a clinical breakthrough to a routine standard of care, is where most of the real uncertainty in the BCI field actually lives. And every potential application starts that journey from a different place, against a different existing standard it has to either displace or create from nothing.
Framed that way, the useful questions change. Where does current care leave the clearest, most undeniable gap? For which patients can BCI do something meaningfully better than existing treatment? What would clinicians, patients, and payers need to believe before intervention seems reasonable? What evidence would build that belief? And which specific behaviors, identification of patients, referral patterns, coverage decisions, would need to shift for adoption to actually happen?
History suggests the strongest entry point isn't necessarily the biggest potential market. It's the narrowest one where the case for change is most obvious: a clear gap, a clearly identifiable patient, a benefit substantial enough to justify the risk, and evidence strong enough to bring clinicians and payers into agreement. Lock that down, and the market stops treating the technology as merely capable of an outcome. It starts expecting that outcome for that kind of patient. From there, the population it serves can widen, the threshold for intervention can shift, and what began as a narrow use case can become ordinary practice.
Some of this groundwork is already underway, not hypothetically but right now. The Implantable BCI Collaborative Community is actively developing outcome measures, clinical practice guidance, and payer frameworks. CMS and the FDA have proposed a pathway called RAPID that would pull coverage considerations earlier into the evidence-development process, before a technology is fully mature. The criteria that will eventually decide which BCI applications succeed commercially are starting to take shape now, while the field is still young enough to be shaped.
A recent analysis in Health Affairs puts this in concrete terms. Demonstrating that a BCI can control someone's environment or let them play a video game shows real technical capability. It doesn't automatically establish medical necessity in the eyes of Medicare. Communication applications, by contrast, already have coverage precedent to build on. That gap between technical possibility and medical necessity is exactly where a lot of promising BCI work could stall, not for lack of engineering progress, but for lack of a clear path to coverage and routine clinical use.
A breakthrough in bandwidth or signal fidelity or reduced invasiveness can open extraordinary new possibilities for patients. But its real-world value depends on whether those possibilities change what clinicians, payers, and families believe should happen for a given patient, and then change what they actually do.
The technology race will determine what BCI can do. A separate and arguably more consequential race, over evidence, coverage criteria, and clinical behavior, will determine which of those capabilities actually become the standard of care. For patients and families watching this field for hope, that second race deserves just as much attention as the one making headlines.
Tags
Original Sources
The BCI Race Everyone is Watching May Be the Wrong One - MedCity News
↗ https://medcitynews.com/2026/11/the-bci-race-everyone-is-watching-may-be-the-wrong-one
About the author
Amara's entry point into AI was an epidemiology role at a London research hospital, where she spent five years studying how digital health tools reached — or conspicuously failed to reach — underserved communities. Watching early algorithmic systems in healthcare quietly entrench existing inequalities, she redirected her career toward the systemic consequences of AI at scale. She covers AI through an unflinching lens: who benefits, who bears the cost, and what evidence actually says versus what the press release claims. Her writing is calm and precise, but she doesn't mistake balance for neutrality.
More from The Steward →This Week's Edition
18 November 2026
29 articles
Related Articles

Who Decides If Your Treatment Is Medically Necessary? Industry Leaders Say It Shouldn't Be AI Alone
Policy & Regulation · 6 min

Epic Systems Pushes Back on Antitrust Criticism, Pledges Broader AI Data Access
Policy & Regulation · 5 min

AI Is Showing Up in Court Filings. Courts Can't Yet Agree on How to Prove It
Policy & Regulation · 6 min
Related Articles

Who Decides If Your Treatment Is Medically Necessary? Industry Leaders Say It Shouldn't Be AI Alone
Policy & Regulation · 6 min

Epic Systems Pushes Back on Antitrust Criticism, Pledges Broader AI Data Access
Policy & Regulation · 5 min

AI Is Showing Up in Court Filings. Courts Can't Yet Agree on How to Prove It
Policy & Regulation · 6 min
More Stories
© 2026 Cedar & Bloom. All rights reserved.